Debt to Equity Ratio Chart

View Debt to Equity Ratio for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.0854
March 31, 2026 0.0861
December 31, 2025 0.0951
September 30, 2025 0.0874
June 30, 2025 0.0904
March 31, 2025 0.092
December 31, 2024 0.1001
September 30, 2024 0.0922
June 30, 2024 0.0959
March 31, 2024 0.1002
December 31, 2023 0.1041
September 30, 2023 0.1085
June 30, 2023 0.1125
March 31, 2023 0.115
December 31, 2022 0.1192
September 30, 2022 0.126
June 30, 2022 0.1305
March 31, 2022 0.1356
December 31, 2021 0.1438
September 30, 2021 0.1564
June 30, 2021 0.1783
March 31, 2021 0.2252
December 31, 2020 0.2445
September 30, 2020 0.2661
June 30, 2020 0.2447
Date Value
March 31, 2020 0.0589
December 31, 2019 0.0644
September 30, 2019 0.0678
June 30, 2019 0.0729
March 31, 2019 0.0752
December 31, 2018 0.0809
September 30, 2018 0.0899
June 30, 2018 0.0982
March 31, 2018 0.1073
December 31, 2017 0.1145
September 30, 2017 0.1161
June 30, 2017 0.127
March 31, 2017 0.1454
December 31, 2016 0.1076
September 30, 2016 0.0851
June 30, 2016 0.0887
March 31, 2016 0.0962
December 31, 2015 0.0993
September 30, 2015 0.1198
June 30, 2015 0.1162
March 31, 2015 0.159
December 31, 2014 0.18
September 30, 2014 0.2215
June 30, 2014 0.2186
March 31, 2014 0.2402

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 2.206
Gilead Sciences, Inc. 2.219
AbbVie, Inc. -11.93
Vertex Pharmaceuticals, Inc. 0.0977
Amgen, Inc. 4.903